AIRLINK 151.71 Decreased By ▼ -4.00 (-2.57%)
BOP 10.05 Decreased By ▼ -0.26 (-2.52%)
CNERGY 7.30 Decreased By ▼ -0.35 (-4.58%)
CPHL 85.11 Decreased By ▼ -3.06 (-3.47%)
FCCL 46.57 Decreased By ▼ -0.79 (-1.67%)
FFL 15.78 Decreased By ▼ -0.34 (-2.11%)
FLYNG 54.86 Decreased By ▼ -3.15 (-5.43%)
HUBC 136.89 Decreased By ▼ -1.63 (-1.18%)
HUMNL 11.25 Decreased By ▼ -0.29 (-2.51%)
KEL 5.34 Decreased By ▼ -0.13 (-2.38%)
KOSM 5.63 Increased By ▲ 0.17 (3.11%)
MLCF 82.84 Decreased By ▼ -0.91 (-1.09%)
OGDC 208.86 Decreased By ▼ -3.19 (-1.5%)
PACE 6.05 Increased By ▲ 0.19 (3.24%)
PAEL 41.46 Decreased By ▼ -1.76 (-4.07%)
PIAHCLA 22.38 Increased By ▲ 0.62 (2.85%)
PIBTL 8.19 Decreased By ▼ -0.23 (-2.73%)
POWER 13.80 Decreased By ▼ -0.56 (-3.9%)
PPL 167.09 Decreased By ▼ -3.90 (-2.28%)
PRL 32.17 Decreased By ▼ -1.32 (-3.94%)
PTC 24.43 Decreased By ▼ -1.07 (-4.2%)
SEARL 89.83 Decreased By ▼ -3.06 (-3.29%)
SSGC 41.52 Decreased By ▼ -0.40 (-0.95%)
SYM 14.86 Decreased By ▼ -0.14 (-0.93%)
TELE 7.69 Decreased By ▼ -0.13 (-1.66%)
TPLP 9.14 Decreased By ▼ -0.17 (-1.83%)
TRG 63.20 Decreased By ▼ -1.02 (-1.59%)
WAVESAPP 9.14 Decreased By ▼ -0.28 (-2.97%)
WTL 1.45 Increased By ▲ 0.08 (5.84%)
YOUW 4.15 Decreased By ▼ -0.04 (-0.95%)
BR100 13,037 Decreased By -207.6 (-1.57%)
BR30 37,726 Decreased By -745.3 (-1.94%)
KSE100 122,144 Decreased By -1949.6 (-1.57%)
KSE30 36,883 Decreased By -653.4 (-1.74%)

ROME: A top official in the European Medicines Agency said it might be worth abandoning AstraZeneca’s coronavirus vaccine for all age groups where alternatives are available, in an interview published Sunday.

Marco Cavaleri, the EMA’s head of vaccine strategy, also told Italy’s La Stampa newspaper that the Johnson & Johnson jab should be preferentially used for the over 60s.

Both so-called viral vector vaccines are authorised for everyone over 18 but have been dogged by reports of rare blood clots. The EU has also authorised two mRNA vaccines, Pfizer/BioNTech and Moderna.

Italy on Saturday restricted AstraZeneca vaccines to people aged 60 and over following concerns about the heightened health risks for younger people.

Asked if it would not be better to ban AstraZeneca including for the over 60s, Cavaleri said: “Yes, and it is an option that many countries, such as France and Germany, are considering in the light of the increased availability of mRNA vaccines.

“However, incidents were very rare and after the first dose. It is true that there is less data on the second dose, but in the United Kingdom it (the vaccination programme) is going well.”

He added: “Among young people the risks of illness decrease, and the message for them could be to use preferentially the mRNA vaccines, but the choice is left to individual states.”

Comments

Comments are closed.